These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 26920690)

  • 21. The NMDA receptor as a therapeutic target in major depressive disorder.
    Pittenger C; Sanacora G; Krystal JH
    CNS Neurol Disord Drug Targets; 2007 Apr; 6(2):101-15. PubMed ID: 17430148
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The glycine site of NMDA receptors: A target for cognitive enhancement in psychiatric disorders.
    Peyrovian B; Rosenblat JD; Pan Z; Iacobucci M; Brietzke E; McIntyre RS
    Prog Neuropsychopharmacol Biol Psychiatry; 2019 Jun; 92():387-404. PubMed ID: 30738126
    [TBL] [Abstract][Full Text] [Related]  

  • 23. NMDA receptor antagonists for depression: Critical considerations.
    Serafini G; Gonda X; Rihmer Z; Pompili M; Girardi P; Nasrallah HA; Amore M
    Ann Clin Psychiatry; 2015 Aug; 27(3):213-20. PubMed ID: 26247220
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The rapid-onset antidepressant effect of ketamine: More surprises?
    Raffa RB; Pergolizzi JV; Taylor R;
    J Clin Pharm Ther; 2018 Apr; 43(2):308-311. PubMed ID: 29178131
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differentially regulated targets in the fast-acting antidepressant effect of (R)-ketamine: A systems biology approach.
    Scotton E; Casa PL; de Abreu FP; de Avila E Silva S; Wilges RLB; Rossetto MV; Géa LP; Rosa AR; Colombo R
    Pharmacol Biochem Behav; 2023 Feb; 223():173523. PubMed ID: 36731751
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Importance of Exploring N-Methyl-D-Aspartate (NMDA) as a Future Perspective Target in Depression.
    Bhatia NY; Ved HS; Kale PP; Doshi GM
    CNS Neurol Disord Drug Targets; 2022; 21(10):1004-1016. PubMed ID: 35352638
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting glutamate signalling in depression: progress and prospects.
    Murrough JW; Abdallah CG; Mathew SJ
    Nat Rev Drug Discov; 2017 Jul; 16(7):472-486. PubMed ID: 28303025
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An Update on Glutamatergic System in Suicidal Depression and on the Role of Esketamine.
    De Berardis D; Tomasetti C; Pompili M; Serafini G; Vellante F; Fornaro M; Valchera A; Perna G; Volpe U; Martinotti G; Fraticelli S; Di Giannantonio M; Kim YK; Orsolini L
    Curr Top Med Chem; 2020; 20(7):554-584. PubMed ID: 32003691
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Glutamate-Based Drug Discovery for Novel Antidepressants.
    Pałucha-Poniewiera A; Pilc A
    Expert Opin Drug Discov; 2016 Sep; 11(9):873-83. PubMed ID: 27409299
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rapid-onset antidepressant efficacy of glutamatergic system modulators: the neural plasticity hypothesis of depression.
    Wang J; Jing L; Toledo-Salas JC; Xu L
    Neurosci Bull; 2015 Feb; 31(1):75-86. PubMed ID: 25488282
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of calcium, glutamate and NMDA in major depression and therapeutic application.
    Deutschenbaur L; Beck J; Kiyhankhadiv A; Mühlhauser M; Borgwardt S; Walter M; Hasler G; Sollberger D; Lang UE
    Prog Neuropsychopharmacol Biol Psychiatry; 2016 Jan; 64():325-33. PubMed ID: 25747801
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Survey of NMDA Receptor-related Biomarkers for Depression.
    Chen YM; Lin CH; Lane HY
    Curr Pharm Des; 2020; 26(2):228-235. PubMed ID: 31969091
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antidepressant actions of ketamine: from molecular mechanisms to clinical practice.
    Monteggia LM; Zarate C
    Curr Opin Neurobiol; 2015 Feb; 30():139-43. PubMed ID: 25562451
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Glutamate and its receptors in the pathophysiology and treatment of major depressive disorder.
    Niciu MJ; Ionescu DF; Richards EM; Zarate CA
    J Neural Transm (Vienna); 2014 Aug; 121(8):907-24. PubMed ID: 24318540
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neurobiology of rapid-acting antidepressants: convergent effects on GluA1-synaptic function.
    Duman RS; Shinohara R; Fogaça MV; Hare B
    Mol Psychiatry; 2019 Dec; 24(12):1816-1832. PubMed ID: 30894661
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rapid acting antidepressants in the mTOR pathway: Current evidence.
    K V A; Mohan AS; Chakravarty S
    Brain Res Bull; 2020 Oct; 163():170-177. PubMed ID: 32739296
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular and Cellular Mechanisms of Rapid-Acting Antidepressants Ketamine and Scopolamine.
    Wohleb ES; Gerhard D; Thomas A; Duman RS
    Curr Neuropharmacol; 2017; 15(1):11-20. PubMed ID: 26955968
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ketamine and the next generation of antidepressants with a rapid onset of action.
    Machado-Vieira R; Salvadore G; Diazgranados N; Zarate CA
    Pharmacol Ther; 2009 Aug; 123(2):143-50. PubMed ID: 19397926
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Glutamatergic approaches in major depressive disorder: focus on ketamine, memantine and riluzole.
    Owen RT
    Drugs Today (Barc); 2012 Jul; 48(7):469-78. PubMed ID: 22844658
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
    Zarate CA; Singh JB; Carlson PJ; Brutsche NE; Ameli R; Luckenbaugh DA; Charney DS; Manji HK
    Arch Gen Psychiatry; 2006 Aug; 63(8):856-64. PubMed ID: 16894061
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.